1. Home
  2. AKRO vs AMBA Comparison

AKRO vs AMBA Comparison

Compare AKRO & AMBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • AMBA
  • Stock Information
  • Founded
  • AKRO 2017
  • AMBA 2004
  • Country
  • AKRO United States
  • AMBA United States
  • Employees
  • AKRO N/A
  • AMBA N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • AMBA Semiconductors
  • Sector
  • AKRO Health Care
  • AMBA Technology
  • Exchange
  • AKRO Nasdaq
  • AMBA Nasdaq
  • Market Cap
  • AKRO 3.9B
  • AMBA 3.3B
  • IPO Year
  • AKRO 2019
  • AMBA N/A
  • Fundamental
  • Price
  • AKRO $49.65
  • AMBA $52.64
  • Analyst Decision
  • AKRO Strong Buy
  • AMBA Buy
  • Analyst Count
  • AKRO 8
  • AMBA 12
  • Target Price
  • AKRO $82.50
  • AMBA $80.83
  • AVG Volume (30 Days)
  • AKRO 1.9M
  • AMBA 856.7K
  • Earning Date
  • AKRO 05-12-2025
  • AMBA 05-29-2025
  • Dividend Yield
  • AKRO N/A
  • AMBA N/A
  • EPS Growth
  • AKRO N/A
  • AMBA N/A
  • EPS
  • AKRO N/A
  • AMBA N/A
  • Revenue
  • AKRO N/A
  • AMBA $316,264,000.00
  • Revenue This Year
  • AKRO N/A
  • AMBA $20.37
  • Revenue Next Year
  • AKRO N/A
  • AMBA $11.56
  • P/E Ratio
  • AKRO N/A
  • AMBA N/A
  • Revenue Growth
  • AKRO N/A
  • AMBA 44.54
  • 52 Week Low
  • AKRO $17.86
  • AMBA $38.86
  • 52 Week High
  • AKRO $58.40
  • AMBA $85.15
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 63.34
  • AMBA 39.68
  • Support Level
  • AKRO $44.94
  • AMBA $60.88
  • Resistance Level
  • AKRO $49.29
  • AMBA $63.64
  • Average True Range (ATR)
  • AKRO 3.33
  • AMBA 2.56
  • MACD
  • AKRO 0.67
  • AMBA -0.67
  • Stochastic Oscillator
  • AKRO 86.02
  • AMBA 13.48

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About AMBA Ambarella Inc.

Ambarella Inc is a developer of semiconductor processing solutions for high-definition video capture, sharing, and display. The firm's solutions are sold to original design manufacturers and original equipment manufacturers to be designed for use in infrastructure broadcast encoders, wearable device cameras, automotive cameras, and security cameras. Ambarella's system-on-a-chip designs, based on its proprietary technology platform, are highly configurable to applications in various end markets. Geographical presence in Taiwan, Asia Pacific, Europe, North America, and the United States. The firm derives the majority of its revenue from Taiwan.

Share on Social Networks: